Skip to main content

People

Christian Angermayer

Co-founder and Co-Chair of the Board

Christian Angermayer is an entrepreneur and investor as well as the founder of Apeiron Investment Group, his family office and asset management business. Apeiron focuses on Life Sciences, FinTech/InsurTech/PropTech & Crypto and DeepTech (e.g. SpaceTech, AI, etc.). In these sectors, Apeiron has a deep experience and a proven track record of more than 20 years.

Shannon Klinger

Independent Board Member

Shannon Thyme Klinger is the Chief Legal Officer of Moderna, Inc. She has over 25 years of global leadership experience in the pharmaceutical industry across a wide range of functional areas, including legal, compliance, IP, licensing, mergers and acquisitions, public/government affairs, communications, risk management, quality, and regulatory affairs. She is a recognized thought leader in the areas of ESG, social intrapreneurship, and diversity, equity, and inclusion.

Throughout her career, she has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, and championing the responsible use of data.

Ms. Klinger currently serves as a member of the board of directors of the Association of Corporate Counsel and has previously served on the board of directors of the SIX Group and Rafael Holdings Inc.

Teresa Deluca, MD, MBA

Member of the Board of Directors

Shannon Thyme Klinger is the Chief Legal Officer of Moderna, Inc. She has over 25 years of global leadership experience in the pharmaceutical industry across a wide range of functional areas, including legal, compliance, IP, licensing, mergers and acquisitions, public/government affairs, communications, risk management, quality, and regulatory affairs. She is a recognized thought leader in the areas of ESG, social intrapreneurship, and diversity, equity, and inclusion. Throughout her career, she has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, and championing the responsible use of data. Ms. Klinger currently serves as a member of the board of directors of the Association of Corporate Counsel and has previously served on the board of directors of the SIX Group and Rafael Holdings Inc.

Aaron Weaver, CFA

Co-Chair of the Board

Aaron is a seasoned investor and operator of life science companies. He has provided expert counsel on numerous types of capital market issuances, emerging markets debt, covered bonds, high yield and restructurings. He has lead investor relations experience across several portfolios.

Gregory Weaver, MBA

Member of the Board of Directors

Greg Weaver has over 25 years of corporate strategic financial leadership as a career Chief Financial Officer (CFO) and board member in the biotech/medtech industry, guiding fundraising, capital markets, investor relations, financial reporting, and business operations planning. Greg Weaver currently serves as the CFO of BioIntelliSense, a US privately-held medtech company. Greg Weaver has served as a public biotech board member continuously since 2005, including as audit and compensation committee chairman, currently with Atossa Therapeutics, and formerly with Noxxon/TME Pharma N.V. (Berlin), Egalet Pharma, Celsion Therapeutics, and Oryzon (Barcelona).

Greg Weaver holds a B.S. in Accounting from Trinity University (Texas), an MBA from Boston College, and a US CPA certification. Greg Weaver has served in the US Air Force. He also serves on the board of the not-for-profit HarborPath, focused on serving patients suffering from AIDS and opioid addiction.

Aksana Labokha, PhD

Chief Executive Officer

Aksana brings 10+ years of experience in the life science and healthcare industry, including early-stage business development, company building, and venture. At Rejuveron she oversees investments, deal sourcing and contributes to strategic expansion of our portfolio companies.

Caleb Morgret, CFA

Chief Financial Officer

Caleb has over 20 years of international finance experience across multiple sectors and geographies. He has worked in CFO roles as well as investment banking and over the course of his career has executed ~$30 billion of equity and debt financings spanning numerous industries and markets (US, Europe, and Asia).

Karim Allam, MBA, LLM, CCP

Chief Legal & People Officer

Karim brings more than 20 years of experience advising and counseling public and private companies in the biopharmaceutical industry. He has been successful in guiding and executing major transactions, and has experience establishing legal and compliance departments, making them a true business partner.

Gábor Gyülvészi, PhD

Chief Business Officer

Gabor is a seasoned biotech executive whose expertise spans drug discovery and venture capital financing. He has spent close to a decade developing immunotherapy programs and has executed a wide range of investments in both the private and public biotech sectors. In his current role, he focuses on strategic planning, fundraising efforts, and building strategic partnerships with leading pharmaceutical companies.

Matthias Steger, PhD, MBA

Co-founder

Matthias has more than 20 years pharma/biotech experience and is the co-founder of Endogena Therapeutics. As former global head of research and technology partnering at Roche, Matthias set up and managed > 50 collaborations and acquisitions for novel drug modalities, drug discovery technologies, and enabling technologies. He also established Roche’s stem cell research program. An entrepreneur at heart, Matthias set up a pioneering orphan G-protein coupled receptor (GPCR) drug discovery company, which resulted in a successful acquisition. He gained financial experience as an investment banking analyst at Kepler Equities.

Patrick Schnider, PhD

VP Medicinal Chemistry - Rejuveron Telomere Therapeutics

Patrick has worked in the industry as a medicinal chemist and preclinical project team leader for more than 20 years, contributing as an inventor and co-inventor of seven compounds which entered clinical development, with one of these reaching the market.

Prof. Manuel Serrano, PhD

Co-founder & Scientific Advisor - Rejuveron Senescence Therapeutics

Manuel is Group Leader at IRB Barcelona. He is a renowned expert in senescence research and pioneered the concept that cellular senescence is critical to signal tissue damage and to elicit tissue regeneration.

Timothy Cash, PhD

Co-founder & Chief Scientific Officer - Rejuveron Senescence Therapeutics

Tim has over 10 years of experience in the field of cellular damage and oncology working in the prestigious CNIO in Madrid. With previous experience in other longevity therapeutics ventures, he has a focus on the fields of aging and oncology.

Chien Chi Hsiao, PhD

Head of Medicinal Chemistry - Rejuveron Telomere Therapeutics

Chien Chi’s pharma experience spans discovery projects in therapeutic areas of oncology, Alzheimer’s, and infectious disease. In addition to his background in novel therapeutic modalities, he provides expertise in state-of-the-art synthetic methodologies and technologies, including AI software, HTE, and parallel synthesis.

Marianna Feretzaki, PhD

Chief Executive Officer AI - Rejuveron Telomere Therapeutics

Marianna provides expertise in biology, in assay development for drug discovery and leads academic collaborations. A Marie Curie and NIH Fellowship recipient, she brings 20 years of research experience encompassing telomere biology (EPFL) and infectious diseases (Duke University).

Pierre-Antoine Mudry, BBA, MS

Head of Investor Relations & Corporate Finance

Pierre brings eight years of experience in investment banking and financial markets, with strategic coverage of the largest Swiss private banks and family offices and a strong track record in investor relations and raising capital.

Prof. Lee Rubin, PhD

Co-founder - Rejuveron Vascular Therapeutics

Lee Rubin is a Harvard Professor of Stem Cell and Regenerative Biology, and an executive committee member and program leader at the Harvard Stem Cell Institute. His lab studies the common biochemical changes that underlie aging and neurodegeneration.

Prof. Hideyuki Okano, MD, PhD

Member of the Scientific Advisory Board

Hideyuki Okano is Keio University Professor of Stem Cell and Regenerative Biology, and Director, Centre for Supercentenarian Medical Research. His lab studies neural stem cell development and neurogenesis to find regenerative therapies for neurodegenerative disorders.

Lisa Balsiger

Executive Assistant

With over a decade of executive assistance experience, Lisa is a seasoned professional adept at navigating dynamic startup environments. Fluent in English, German, and French, she brings a multilingual edge to seamless communication. Her expertise lies in optimizing efficiency, fostering collaborative environments, and providing invaluable support to executive teams.

Aksana Labokha, PhD

Chief Executive Officer

Aksana brings 10+ years of experience in the life science and healthcare industry, including early-stage business development, company building, and venture. At Rejuveron she oversees investments, deal sourcing and contributes to strategic expansion of our portfolio companies.

Caleb Morgret, CFA

Chief Financial Officer

Caleb has over 20 years of international finance experience across multiple sectors and geographies. He has worked in CFO roles as well as investment banking and over the course of his career has executed ~$30 billion of equity and debt financings spanning numerous industries and markets (US, Europe, and Asia).

Gábor Gyülvészi, PhD

Chief Business Officer

Gabor is a seasoned biotech executive whose expertise spans drug discovery and venture capital financing. He has spent close to a decade developing immunotherapy programs and has executed a wide range of investments in both the private and public biotech sectors. In his current role, he focuses on strategic planning, fundraising efforts, and building strategic partnerships with leading pharmaceutical companies.

Karim Allam, MBA, LLM, CCP

Chief Legal & People Officer

Karim brings more than 20 years of experience advising and counseling public and private companies in the biopharmaceutical industry. He has been successful in guiding and executing major transactions, and has experience establishing legal and compliance departments, making them a true business partner.

Pierre-Antoine Mudry, BBA, MS

Head of Investor Relations & Corporate Finance

Pierre brings eight years of experience in investment banking and financial markets, with strategic coverage of the largest Swiss private banks and family offices and a strong track record in investor relations and raising capital.

Christian Angermayer

Co-founder and Co-Chair of the Board

Christian Angermayer is an entrepreneur and investor as well as the founder of Apeiron Investment Group, his family office and asset management business. Apeiron focuses on Life Sciences, FinTech/InsurTech/PropTech & Crypto and DeepTech (e.g. SpaceTech, AI, etc.). In these sectors, Apeiron has a deep experience and a proven track record of more than 20 years.

Aaron Weaver, CFA

Co-Chair of the Board

Aaron is a seasoned investor and operator of life science companies. He has provided expert counsel on numerous types of capital market issuances, emerging markets debt, covered bonds, high yield and restructurings. He has lead investor relations experience across several portfolios.

Aksana Labokha, PhD

Chief Executive Officer

Aksana brings 10+ years of experience in the life science and healthcare industry, including early-stage business development, company building, and venture. At Rejuveron she oversees investments, deal sourcing and contributes to strategic expansion of our portfolio companies.

Shannon Klinger

Independent Board Member

Shannon Thyme Klinger is the Chief Legal Officer of Moderna, Inc. She has over 25 years of global leadership experience in the pharmaceutical industry across a wide range of functional areas, including legal, compliance, IP, licensing, mergers and acquisitions, public/government affairs, communications, risk management, quality, and regulatory affairs. She is a recognized thought leader in the areas of ESG, social intrapreneurship, and diversity, equity, and inclusion.

Throughout her career, she has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, and championing the responsible use of data.

Ms. Klinger currently serves as a member of the board of directors of the Association of Corporate Counsel and has previously served on the board of directors of the SIX Group and Rafael Holdings Inc.

Teresa Deluca, MD, MBA

Independent Board Member

Shannon Thyme Klinger is the Chief Legal Officer of Moderna, Inc. She has over 25 years of global leadership experience in the pharmaceutical industry across a wide range of functional areas, including legal, compliance, IP, licensing, mergers and acquisitions, public/government affairs, communications, risk management, quality, and regulatory affairs. She is a recognized thought leader in the areas of ESG, social intrapreneurship, and diversity, equity, and inclusion. Throughout her career, she has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, and championing the responsible use of data. Ms. Klinger currently serves as a member of the board of directors of the Association of Corporate Counsel and has previously served on the board of directors of the SIX Group and Rafael Holdings Inc.

Gregory Weaver, MBA

Independent Board Member

Greg Weaver has over 25 years of corporate strategic financial leadership as a career Chief Financial Officer (CFO) and board member in the biotech/medtech industry, guiding fundraising, capital markets, investor relations, financial reporting, and business operations planning. Greg Weaver currently serves as the CFO of BioIntelliSense, a US privately-held medtech company. Greg Weaver has served as a public biotech board member continuously since 2005, including as audit and compensation committee chairman, currently with Atossa Therapeutics, and formerly with Noxxon/TME Pharma N.V. (Berlin), Egalet Pharma, Celsion Therapeutics, and Oryzon (Barcelona).

Greg Weaver holds a B.S. in Accounting from Trinity University (Texas), an MBA from Boston College, and a US CPA certification. Greg Weaver has served in the US Air Force. He also serves on the board of the not-for-profit HarborPath, focused on serving patients suffering from AIDS and opioid addiction.

Prof. Hideyuki Okano, MD, PhD

Member of the Scientific Advisory Board

Hideyuki Okano is Keio University Professor of Stem Cell and Regenerative Biology, and Director, Centre for Supercentenarian Medical Research. His lab studies neural stem cell development and neurogenesis to find regenerative therapies for neurodegenerative disorders.

Matt Kaeberlein PhD

Scientific Advisory Board

  • CEO of Optispan and Affiliate Professor of Oral Health at the University of Washington
  • Founding Director of the University of Washington Healthy Aging and Longevity Research Institute
  • Research focused on understanding the biological mechanisms of aging
Prof. Brian Kennedy PhD

Scientific Advisory Board

  • Former President and CEO of the Buck Institute for Research on Aging
  • Director of the Centre for Healthy Ageing and Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine at National University Singapore
Prof. Lee Rubin, PhD

Co-founder - Rejuveron Vascular Therapeutics

Lee Rubin is a Harvard Professor of Stem Cell and Regenerative Biology, and an executive committee member and program leader at the Harvard Stem Cell Institute. His lab studies the common biochemical changes that underlie aging and neurodegeneration.

Prof. Manuel Serrano, PhD

Co-founder & Scientific Advisor - Rejuveron Senescence Therapeutics

Manuel is Group Leader at IRB Barcelona. He is a renowned expert in senescence research and pioneered the concept that cellular senescence is critical to signal tissue damage and to elicit tissue regeneration.

Patrick Schnider, PhD

VP Medicinal Chemistry - Rejuveron Telomere Therapeutics

Patrick has worked in the industry as a medicinal chemist and preclinical project team leader for more than 20 years, contributing as an inventor and co-inventor of seven compounds which entered clinical development, with one of these reaching the market.

Dr. Suneet Agarwal, MD, PhD

Co-founder Rejuveron Telomere Therapeutics

Associate Professor of Pediatrics, Bostons Childrens Hospital, Harvard Medical School. Suneet is the leading expert on telomere diseases. He has initiated multiple telomere ailment associations and led a multi-center bone marrow transplant clinical trial for patients with Dyskeratosis Congenita and telomere diseases. He brings more than 20 years of experience in DC and telomeropathies.

Prof. Thomas C. Südhof MD, PhD

Founder Boost Neuroscience

  • Dr. Südhof received the Nobel Prize in Physiology or Medicine in 2013
  • Professor in the School of Medicine in the Department of Molecular and Cellular Physiology, and by courtesy in Neurology, and in Psychiatry and Behavioral Sciences at Stanford University
Ann Beliën PhD

Founder & CEO Rejuvenate Biomed

  • 17+ years of experience in drug development from bench to market
  • PhD from the University of Irchel, Zürich, Switzerland and a master’s degree from the Free University of Brussels (VUB), Belgium.
  • Postdoc at ETH, Zürich, Switzerland

Our Corporate Values:

Make therapies happen

Make it sustainable

Make yourself curious

Our Vision for the Future: